[The clinical course of oxyphilic carcinoma of the thyroid].
In a total of 1665 patients with malignant thyroid neoplasms 90 oxyphilic thyroid carcinomas (OTC) were found of whom 55 could be re-examined and newly classified. Morphological and clinical parameters influencing the clinical course were determined. During a mean follow-up period of 6.5 y metastases or local recurrent disease occurred in 12 patients (24%). Apart from 3 early manifestations of metastases, 9 patients developed recurrent disease within, on average, 4.7 y after thyroidectomy: local lymph node metastases and local recurrences occurred within an average of 5.4 y, distant metastases after only 2.7 y. Thyroglobulin proved to be reliable for follow-up with a sensitivity of 88% on levothyroxine and 75% on endogenous TSH-stimulation (specificity: 98%). The frequency of metastases and local recurrences correlated with age at the time of tumor diagnosis, the degree of invasiveness and the local tumor extension (pT4 vs. pT1-3), whereas other factors such as the absolute diameter of the tumor or patient's sex had no influence on the clinical course. The survival probability for 5 and 10 years was 95 and 75%, respectively. All OTC patients should be examined regularly at least once a year by cervical sonography and thyroglobulin measurement. Because 18% recurrences occurred within 4.7 y such examinations should be repeated beyond year 5 after thyroidectomy.
Hamann
A
A
Abteilung Nuklearmedizin und spezielle Biophysik, Medizinische Hochschule Hannover, FRG.
Gratz
K F
KF
Soudah
B
B
Fritsch
R S
RS
Georgii
A
A
Hundeshagen
H
H
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D002277:Carcinoma / Q000145:classification / Q000453:epidemiology* / Q000473:pathology; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000145:classification / Q000453:epidemiology* / Q000473:pathology
D014408:Biomarkers, Tumor; D013954:Thyroglobulin
Klinisches Verhalten oxyphiler Karzinome der Schilddrüse.